A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents with Pembrolizumab (MK-3475) in Participants with Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment [KEYMAKER-U06]
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
Merck Sharp & Dohme